Page 19«..10..18192021..3040..»

Category Archives: Muscular Dystrophy Treatment

Global Gene Therapy Market is Projected to Reach USD 13.0 Billion by 2024 from USD 3.8 Billion in 2019, at a CAGR of 27.8% – ResearchAndMarkets.com -…

Posted: Published on February 5th, 2020

DUBLIN--(BUSINESS WIRE)--Feb 5, 2020-- The "Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering. High incidence of cancer & other target diseases is a major factor driving the growth of the gene therapy market The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of this market. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Global Gene Therapy Market is Projected to Reach USD 13.0 Billion by 2024 from USD 3.8 Billion in 2019, at a CAGR of 27.8% – ResearchAndMarkets.com -…

Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option – Yahoo Finance

Posted: Published on February 5th, 2020

Catabasis Pharmaceuticals, Inc. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option – Yahoo Finance

Global Gene Therapy Industry Outlook 2020-2024 – Strong Product Pipeline Gives Rise to Lucrative Growth Opportunities – Yahoo Finance

Posted: Published on February 5th, 2020

DUBLIN, Jan. 30, 2020 /PRNewswire/ -- The "Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Global Gene Therapy Industry Outlook 2020-2024 – Strong Product Pipeline Gives Rise to Lucrative Growth Opportunities – Yahoo Finance

French cancer-focused microbiome player is flush with 18M Series B injection – Endpoints News

Posted: Published on February 5th, 2020

Last year, the death of an immuno-compromised elderly patient in a fecal microbiota transplantation trial due to a donation that contained a rare type of E. coli bacteria sent shivers across the field. The incident marred an otherwise exploding field of drug development that backed replenishing the gut with good bacteria as a safe and effective means to fortify the immune system to fight disease. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on French cancer-focused microbiome player is flush with 18M Series B injection – Endpoints News

Duchenne Muscular Dystrophy: Muscle Weakness That Begins In This Body Part Could Be A Warning Sign – International Business Times

Posted: Published on February 3rd, 2020

KEY POINTS Duchenne muscular dystrophy (DMD) is a rare muscle disorder affecting about 1 in 3,500 male births globally. The condition is usually recognized between the ages of three and six. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Duchenne Muscular Dystrophy: Muscle Weakness That Begins In This Body Part Could Be A Warning Sign – International Business Times

Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH – Xconomy

Posted: Published on February 3rd, 2020

Xconomy Boston Sotatercept was one of the first compounds to emerge from the labs of Acceleron Pharma, but it became a forgotten piece of the companys pipeline. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH – Xconomy

Six patients with rare blood disease are doing well after gene therapy clinical trial – UCLA Newsroom

Posted: Published on February 3rd, 2020

Sarah C.P. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Six patients with rare blood disease are doing well after gene therapy clinical trial – UCLA Newsroom

Did FDA lower the bar in its Sarepta decisions? We discuss – STAT

Posted: Published on January 27th, 2020

Containing new coronavirus may not be feasible, experts say, Containing new coronavirus may not be feasible, experts say, as they warn of possible sustained global DNA sleuths read the coronavirus genome, tracing its origins DNA sleuths read the coronavirus genome, tracing its origins and looking for dangerous mutations How fast can biotech come up with a vaccine How fast can biotech come up with a vaccine for the latest outbreak? Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Did FDA lower the bar in its Sarepta decisions? We discuss – STAT

Is the Medication You’re Taking Worth Its Price? – Undark Magazine

Posted: Published on January 27th, 2020

Austin was three years old and Max was a newborn when their mother, Jenn McNary, learned they had a rare genetic condition called Duchenne muscular dystrophy. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Is the Medication You’re Taking Worth Its Price? – Undark Magazine

Santhera Reports Net Revenues 2019 and Highlights Pipeline Progress – GlobeNewswire

Posted: Published on January 27th, 2020

Pratteln, Switzerland, January27, 2020 Santhera Pharmaceuticals (SIX: SANN) generated net revenues of CHF27.9 million in 2019 from sales of Raxone for the treatment of Lebers hereditary optic neuropathy (LHON), which was out-licensed to Chiesi Group from August 2019. The Company made strong progress in advancing its lead neuromuscular compounds Puldysa (idebenone) and vamorolone towards market entry and regulatory submission, respectively. We are pleased about Santheras strong progress in 2019 and are excited about the prospects 2020 holds, said Dario Eklund, CEO of Santhera Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Santhera Reports Net Revenues 2019 and Highlights Pipeline Progress – GlobeNewswire

Page 19«..10..18192021..3040..»